Cargando…

Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial

Adipokines are mediators of body composition and are involved in obesity-related complications such as cardiovascular disease. Omega-3 supplementation has not been studied in the setting of body composition and follistatin-like 1 (FSTL1) levels in patients with coronary artery disease (CAD). This st...

Descripción completa

Detalles Bibliográficos
Autores principales: Jafari Salim, Shirin, Alizadeh, Shahab, Djalali, Mahmoud, Nematipour, Ebrahim, Hassan Javanbakht, Mohammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675253/
https://www.ncbi.nlm.nih.gov/pubmed/28826313
http://dx.doi.org/10.1177/1557988317720581
_version_ 1783276902335643648
author Jafari Salim, Shirin
Alizadeh, Shahab
Djalali, Mahmoud
Nematipour, Ebrahim
Hassan Javanbakht, Mohammad
author_facet Jafari Salim, Shirin
Alizadeh, Shahab
Djalali, Mahmoud
Nematipour, Ebrahim
Hassan Javanbakht, Mohammad
author_sort Jafari Salim, Shirin
collection PubMed
description Adipokines are mediators of body composition and are involved in obesity-related complications such as cardiovascular disease. Omega-3 supplementation has not been studied in the setting of body composition and follistatin-like 1 (FSTL1) levels in patients with coronary artery disease (CAD). This study aimed to investigate the effect of omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation on body composition indices and serum levels of FSTL1 in CAD patients. A total of 42 male (aged 45–65 years) subjects with angiographically confirmed CAD were included in this randomized, double-blind, placebo-controlled trial study. The subjects were randomly divided into omega-3 and placebo groups. During the 8-week intervention, the omega-3 group received 1,200 mg of omega-3 daily, while the placebo group received paraffin. Before and after the study, anthropometric measurements and body composition components were taken; serum FSTL1 levels were assessed by an enzyme-linked immunosorbent assay (ELISA) kit. In the omega-3 group, a significant 27.6% increase in serum FSTL1 was seen after 8 weeks of intervention (p = .001), but no significant difference in posttreatment levels of FSTL1 was observed between the two groups (p > .05). At the end of the study, a significant decrease in low-density lipoprotein cholesterol (LDL-C; 94.29 ± 22.04 vs. 112.24 ± 24.5; p = .01) and high-sensitivity C-reactive protein (hs-CRP; 1.92 ± 0.79 vs. 3.19 ± 2.51; p = .03) concentration was detected between the two groups. Changes in fasting blood sugar, fasting insulin, body composition, and anthropometric parameters were not significant within and between the groups. Oral omega-3 might increase FSTL1 and decrease LDL-C and hs-CRP concentrations in CAD patients. However, omega-3 supplementation did not have any effect on FSTL1 levels between the groups.
format Online
Article
Text
id pubmed-5675253
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-56752532017-12-12 Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial Jafari Salim, Shirin Alizadeh, Shahab Djalali, Mahmoud Nematipour, Ebrahim Hassan Javanbakht, Mohammad Am J Mens Health Articles Adipokines are mediators of body composition and are involved in obesity-related complications such as cardiovascular disease. Omega-3 supplementation has not been studied in the setting of body composition and follistatin-like 1 (FSTL1) levels in patients with coronary artery disease (CAD). This study aimed to investigate the effect of omega-3 polyunsaturated fatty acid (ω-3 PUFA) supplementation on body composition indices and serum levels of FSTL1 in CAD patients. A total of 42 male (aged 45–65 years) subjects with angiographically confirmed CAD were included in this randomized, double-blind, placebo-controlled trial study. The subjects were randomly divided into omega-3 and placebo groups. During the 8-week intervention, the omega-3 group received 1,200 mg of omega-3 daily, while the placebo group received paraffin. Before and after the study, anthropometric measurements and body composition components were taken; serum FSTL1 levels were assessed by an enzyme-linked immunosorbent assay (ELISA) kit. In the omega-3 group, a significant 27.6% increase in serum FSTL1 was seen after 8 weeks of intervention (p = .001), but no significant difference in posttreatment levels of FSTL1 was observed between the two groups (p > .05). At the end of the study, a significant decrease in low-density lipoprotein cholesterol (LDL-C; 94.29 ± 22.04 vs. 112.24 ± 24.5; p = .01) and high-sensitivity C-reactive protein (hs-CRP; 1.92 ± 0.79 vs. 3.19 ± 2.51; p = .03) concentration was detected between the two groups. Changes in fasting blood sugar, fasting insulin, body composition, and anthropometric parameters were not significant within and between the groups. Oral omega-3 might increase FSTL1 and decrease LDL-C and hs-CRP concentrations in CAD patients. However, omega-3 supplementation did not have any effect on FSTL1 levels between the groups. SAGE Publications 2017-08-21 2017-11 /pmc/articles/PMC5675253/ /pubmed/28826313 http://dx.doi.org/10.1177/1557988317720581 Text en © The Author(s) 2017 http://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page(https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Articles
Jafari Salim, Shirin
Alizadeh, Shahab
Djalali, Mahmoud
Nematipour, Ebrahim
Hassan Javanbakht, Mohammad
Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial
title Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial
title_full Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial
title_fullStr Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial
title_full_unstemmed Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial
title_short Effect of Omega-3 Polyunsaturated Fatty Acids Supplementation on Body Composition and Circulating Levels of Follistatin-Like 1 in Males With Coronary Artery Disease: A Randomized Double-Blind Clinical Trial
title_sort effect of omega-3 polyunsaturated fatty acids supplementation on body composition and circulating levels of follistatin-like 1 in males with coronary artery disease: a randomized double-blind clinical trial
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5675253/
https://www.ncbi.nlm.nih.gov/pubmed/28826313
http://dx.doi.org/10.1177/1557988317720581
work_keys_str_mv AT jafarisalimshirin effectofomega3polyunsaturatedfattyacidssupplementationonbodycompositionandcirculatinglevelsoffollistatinlike1inmaleswithcoronaryarterydiseasearandomizeddoubleblindclinicaltrial
AT alizadehshahab effectofomega3polyunsaturatedfattyacidssupplementationonbodycompositionandcirculatinglevelsoffollistatinlike1inmaleswithcoronaryarterydiseasearandomizeddoubleblindclinicaltrial
AT djalalimahmoud effectofomega3polyunsaturatedfattyacidssupplementationonbodycompositionandcirculatinglevelsoffollistatinlike1inmaleswithcoronaryarterydiseasearandomizeddoubleblindclinicaltrial
AT nematipourebrahim effectofomega3polyunsaturatedfattyacidssupplementationonbodycompositionandcirculatinglevelsoffollistatinlike1inmaleswithcoronaryarterydiseasearandomizeddoubleblindclinicaltrial
AT hassanjavanbakhtmohammad effectofomega3polyunsaturatedfattyacidssupplementationonbodycompositionandcirculatinglevelsoffollistatinlike1inmaleswithcoronaryarterydiseasearandomizeddoubleblindclinicaltrial